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Immunotherapy is gathering momentum as a primary
therapy for cancer patients. However, monotherapies
have limited efficacy in improving outcomes and only
benefit a subset of patients. Combination therapies tar-
geting multiple pathways can augment an immune
response to further improve survival. Here, we demon-
strate that dual anti-OX40/anti-CTLA-4 immunotherapy
generated a potent antigen-specific CD8 T cell response,
enhancing expansion, effector function, and memory T
cell persistence. Importantly, OX40 and CTLA-4 expres-
sion on CD8 T cells was critical to maximally promote
their expansion following combination therapy. Animals
treated with combination therapy and vaccination using
anti-DEC-205-HER2 had significantly improved survival
in a mammary carcinoma model. Vaccination with com-
bination therapy uniquely restricted Th2-cytokine pro-
duction by CD4 cells, relative to combination therapy
alone, and enhanced IFNa production by CD8 and CD4
cells. We observed an increase in MIP-1a/CCL3, MIP-
1b/CCL4, RANTES/CCL5, and GM-CSF production by
CD8 and CD4 T cells following treatment. Furthermore,
this therapy was associated with extensive tumor
destruction and T cell infiltration into the tumor.
Notably, vaccination with combination therapy reversed
anergy and enhanced the expansion and function of
CD8 T cells recognizing a tumor-associated antigen in a
spontaneous model of prostate adenocarcinoma. Collec-
tively, these data demonstrate that the addition of an
anti-DEC-205-HER2 vaccine with combined anti-OX40/
anti-CTLA-4 immunotherapy augmented anti-tumor
CD8 T cell function, while limiting Th2 polarization in
CD4 cells and improving overall survival.
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